Direct oral anticoagulants in chronic thromboembolic pulmonary hypertension

[1]  M. Humbert,et al.  ERS statement on chronic thromboembolic pulmonary hypertension , 2020, European Respiratory Journal.

[2]  M. Humbert,et al.  Safety of Riociguat in Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension with Concomitant Novel Oral Anticoagulants or Vitamin K Antagonist Use: Data from the EXPERT Registry , 2020 .

[3]  S. Kahn,et al.  Direct oral anticoagulants in thrombotic antiphospholipid syndrome associated with chronic thromboembolic pulmonary hypertension , 2020, Journal of thrombosis and haemostasis : JTH.

[4]  S. Rosenkranz,et al.  Systemic Consequences of Pulmonary Hypertension and Right-Sided Heart Failure , 2020, Circulation.

[5]  Sert Sena,et al.  Real-life data of direct anticoagulant use, bleeding risk and venous thromboembolism recurrence in chronic thromboembolic pulmonary hypertension patients: an observational retrospective study , 2020, Pulmonary circulation.

[6]  S. Stevens,et al.  Direct oral anticoagulants in antiphospholipid syndrome with venous thromboembolism: Impact of the European Medicines Agency guidance , 2019, Research and practice in thrombosis and haemostasis.

[7]  L. Bertoletti,et al.  In vitro assessment of P‐gp and BCRP transporter‐mediated drug–drug interactions of riociguat with direct oral anticoagulants , 2020, Fundamental & clinical pharmacology.

[8]  M. Humbert,et al.  2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): supplementary data , 2019 .

[9]  T. Atsumi,et al.  Factor Xa inhibitors for preventing recurrent thrombosis in patients with antiphospholipid syndrome: a longitudinal cohort study , 2019, Lupus.

[10]  P. Corris,et al.  A multicenter study of anticoagulation in operable chronic thromboembolic pulmonary hypertension , 2019, Journal of thrombosis and haemostasis : JTH.

[11]  N. Kim,et al.  Direct oral anticoagulant use and thrombus detection in patients with chronic thromboembolic pulmonary hypertension referred for pulmonary thromboendarterectomy , 2019, Pulmonary hypertension.

[12]  Z. Jing,et al.  Antiphospholipid Syndrome in Chronic Thromboembolic Pulmonary Hypertension: A Well-Defined Subgroup of Patients , 2019, Thrombosis and Haemostasis.

[13]  T. Adam,et al.  Direct oral anticoagulants and warfarin for venous thromboembolism treatment: Trends from 2012 to 2017 , 2019, Research and practice in thrombosis and haemostasis.

[14]  A. Olyaei,et al.  The efficacy and safety of direct oral anticoagulants in patients with chronic renal insufficiency: A review of the literature , 2019, European journal of haematology.

[15]  A. Tincani,et al.  Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. , 2018, Blood.

[16]  R. Giugliano,et al.  Oral Anticoagulation in Patients With Liver Disease. , 2018, Journal of the American College of Cardiology.

[17]  H. Schäfers,et al.  Incidence and characteristics of chronic thromboembolic pulmonary hypertension in Germany , 2018, Clinical Research in Cardiology.

[18]  W. Auger,et al.  Epidemiology and risk factors for chronic thromboembolic pulmonary hypertension. , 2018, Thrombosis research.

[19]  M. Fang,et al.  Dosing Accuracy of Direct Oral Anticoagulants in an Academic Medical Center , 2017, Journal of hospital medicine.

[20]  F. Klok,et al.  Incidence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: a contemporary view of the published literature , 2017, European Respiratory Journal.

[21]  D. Bonderman,et al.  Riociguat for the treatment of pulmonary hypertension: a safety evaluation , 2016, Expert opinion on drug safety.

[22]  Simon Gibbs,et al.  2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. , 2016, Revista espanola de cardiologia.

[23]  K. Buch,et al.  Hospital and intensive care unit management of decompensated pulmonary hypertension and right ventricular failure , 2015, Heart Failure Reviews.

[24]  Simon Gibbs,et al.  [2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension]. , 2015, Kardiologia polska.

[25]  S. Sakao,et al.  Crosstalk between endothelial cell and thrombus in chronic thromboembolic pulmonary hypertension: perspective. , 2013, Histology and histopathology.

[26]  K. Moser,et al.  Pulmonary vascular lesions occurring in patients with chronic major vessel thromboembolic pulmonary hypertension. , 1993, Chest.